Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. (Nasdaq: ZYME) generates frequent news flow as a biotechnology and clinical-stage biopharmaceutical company managing licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics. Company announcements highlight its focus on difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, and its integrated model that combines internal R&D with an asset and royalty aggregation strategy.
News about Zymeworks often centers on clinical trial progress and key data readouts. A major theme is the development of Ziihera ® (zanidatamab-hrii), a HER2-targeted bispecific antibody engineered using the company’s Azymetric™ technology. Press releases have detailed positive Phase 3 HERIZON-GEA-01 results in first-line HER2-positive gastroesophageal adenocarcinoma, as well as regulatory approvals for previously treated HER2-positive biliary tract cancer in the U.S., Europe, and China. Updates also cover the advancement of partnered programs like pasritamig with Johnson & Johnson Innovative Medicine and early-stage data from wholly owned ADC candidates such as ZW191 and ZW251.
Investors following ZYME news can also expect regular coverage of strategic and corporate developments. The company reports on its evolving royalty- and asset-focused strategy, share repurchase authorizations, milestone and royalty revenues from partners, and leadership and board appointments designed to support capital allocation and partnership execution. Participation in major medical and investor conferences, such as ASCO GI and the J.P. Morgan Healthcare Conference, is another recurring topic in its news releases.
This news feed provides a centralized view of Zymeworks’ clinical milestones, partnership updates, financial and strategic announcements, and governance changes, offering context for how the company is executing its stated goal of building a diversified portfolio of revenue-generating healthcare assets alongside an active R&D engine.
Summary not available.
Zymeworks Inc. (Nasdaq: ZYME) presented new data from its clinical and preclinical programs at the 2023 American Association for Cancer Research Annual Meeting. Key highlights include:
- ZW191 showed strong responses in FRα-low expressing patient-derived xenograft models, with positive pharmacokinetic and safety profiles.
- ZW171 effectively killed cancer cells while mitigating risks of toxicity and adverse immune activation.
- ZW251 demonstrated significant anti-tumor activity in various glypican-3-expressing cancer models.
The company aims to advance at least five novel therapeutics into clinical studies by 2027, bolstered by their innovative antibody-drug conjugates and multispecific antibody platforms.
Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company focused on developing innovative biotherapeutics, will report its Q1 2023 financial results on May 8, 2023, after market close. Following this announcement, Zymeworks will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Investors can access the live event and recordings through Zymeworks’ website.
Founded with a mission to address challenging cancers and other serious diseases, Zymeworks specializes in antibody-based therapies using its proprietary Azymetric™ technology. The company is advancing its lead candidate, zanidatamab, and next-generation product zanidatamab zovodotin (ZW49), both targeting HER2-expressing cancers.
Zymeworks Inc. (Nasdaq: ZYME) announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023. Miller brings over 25 years of experience in oncology and corporate development. His expertise is expected to support Zymeworks in its collaboration efforts with Jazz Pharmaceuticals and BeiGene on zanidatamab, a bispecific antibody currently undergoing multiple clinical trials. Kenneth Galbraith, CEO, emphasized Miller's strategic insights will enhance the company's pipeline of drug candidates. Miller's previous roles include leadership positions at Aro Biotherapeutics and Celator Pharmaceuticals, where he contributed to significant collaborations and business strategies that generated substantial revenues. Zymeworks focuses on developing innovative biotherapeutics aimed at improving outcomes for patients with difficult-to-treat cancers.
Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology firm, will participate in two upcoming investor conferences. Management will hold one-on-one meetings and present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25 in location value="LU/ca.on.tornto"Toronto. Additionally, they will participate in the Stifel 2023 Targeted Oncology Days virtually on April 26. Presentations and webcasts will be available on their website. Zymeworks is focused on developing innovative biotherapeutics, including the HER2-targeted bispecific antibody, zanidatamab, currently in various clinical trial phases.
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, announced eleven abstracts accepted for presentation at the American Association for Cancer Research Annual Meeting from April 14-19, 2023, in Orlando, FL. The abstracts will showcase advancements in the company’s antibody drug conjugates, multispecific antibodies, and clinical candidates, including ZW171 and ZW191. The management team will host a conference call on April 18, 2023, at 6:30 pm EST to discuss these developments. The abstracts reflect Zymeworks' commitment to pioneering treatments for difficult-to-treat cancers.
Zymeworks Inc. (ZYME) reported a significant turnaround in 2022, achieving $412.5 million in total revenue, a sharp increase from $26.7 million in 2021. The company posted a net income of $124.3 million ($1.90 per share) compared to a net loss of $211.8 million in the previous year. Cash resources stand at $492.2 million, ensuring a runway through 2026. Key developments include positive Phase 2 study results for zanidatamab and a substantial licensing agreement with Jazz Pharmaceuticals, potentially worth up to $1.76 billion. Zymeworks aims to advance multiple clinical studies and develop five novel product candidates over the next five years.
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences. The management will attend the Barclays Global Healthcare Conference on March 14-15, presenting on March 14 at 10:45 am EST in Miami Beach, FL. Additionally, the team will join the Cantor: The Future of Oncology Virtual Symposium on April 3-4 for virtual meetings and a fireside chat. Presentations and webcasts will be accessible on Zymeworks’ website.
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, will announce its fourth quarter and full year 2022 financial results on March 7, 2023, after market close. A conference call and webcast will follow at 4:30 p.m. EST to discuss the results and provide a corporate update. Interested parties can access the live webcast and replay on Zymeworks' website. The company focuses on developing multifunctional biotherapeutics for difficult-to-treat cancers, with its lead candidate zanidatamab currently in various clinical trials. Zymeworks aims to make impactful advancements in cancer treatment.
Zymeworks Inc. (Nasdaq: ZYME), a biotechnology firm focused on developing multifunctional biotherapeutics, recently announced its participation in two upcoming investor conferences. The first is the Guggenheim Oncology Conference on February 8-9, featuring one-on-one meetings and a fireside chat on February 9 at 2:10 pm ET in New York, NY. The second is the SVB Securities Global Biopharma Conference on February 14-15, with a presentation scheduled for February 14 at 10:40 am ET. All events will be accessible via Zymeworks’ website.